Byrne, M

Straumann, A; Conus, S; Grzonka, P; Kita, H; Kephart, G; Bussmann, C; Beglinger, C; Smith, D A; Patel, J; Byrne, M; Simon, H-U (2010). Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut, 59(1), pp. 21-30. London: BMJ Publishing Group 10.1136/gut.2009.178558

Buse, JB; Rosenstock, J; Sesti, G; Schmidt, WE; Montanya, E; Brett, JH; Zychma, M; Blonde, L; Ahmed, A; Alvarsson, M; Anderson, C; Aoki, A; Aranko, S; Bailey, B; Barbonta, D; Baur, C; Bednarczyk-Kaluzny, M; Blevins, T; Blonde, L; Bode, B; ... (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 374(9683), pp. 39-47. London: Elsevier 10.1016/S0140-6736(09)60659-0